NEW YORK–(BUSINESS WIRE)–WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Twist Bioscience Corporation (NASDAQ: TWST) resulting from allegations that Twist may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased Twist securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=10241 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On November 15, 2022, market analyst Scorpion Capital published a report on Twist. The report alleged, among other things, that Twist is “[t]he latest miniaturized ‘lab-on-a-chip’ scam, just like Theranos, Berkeley Lights, and other failures” and “[a] ticking time bomb that we believe is resorting to a Worldcom-esque accounting fraud[.]” The report also alleged that “Twist’s reported gross margins of 45% are simply implausible,” and alleged that “[m]ultiple competitors internally refer to Twist’s price dumping and customer subsidy scheme as a ‘Ponzi’”.
On this news, Twist’s stock…
